drugset / Trial / NCT01802814
International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010
Phase 3
Completed
700 enrolled
Charite University, Berlin, Germany
Australian & New Zealand Children's Haematology/Oncology Group · collabCentral Manchester University (Co-Sponsor United Kingdom) · collabCentre Hospitalier Universitaire de Nice · collabCopenhagen University Hospital (Rigshospitalet) (Co-Sponsor Copenhagen) · collabEuropean Organisation for Research and Treatment of Cancer - EORTC · collabInstituto Português de Oncologia de Lisboa (Co-Sponsor Lisboa) · collabNational Hospital Organization Nagoya Medical Center (Co-Sponsor Japan) · collabOslo University Hospital (Co-Sponsor Oslo) · collabOspedale Pediatrico Bambino Gesù (Co-Sponsor Italy) · collabOur Lady's Chilrden's Hospital (Co-Sponsor Ireland) · collabPrinses Máxima Centrum (Co-Sponsor Netherlands) · collabSpanish Society of Pediatric Hematology and Oncology (SEHOP) (Co-Sponsor Spain) · collabSt. Anna Kinderkrebsforschung (Co-Sponsor Austria) · collabTel Aviv Sourasky Medical Centre (Co-Sponsor Israel) · collabTurku University (Co-Sponsor Finland) · collabUniversity Children's Hospital, Zurich · collabUniversity Hospital, Motol · collabWroclaw Medical University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The main goal of this study is to improve the outcome of children and adolescents with standard risk (SR) first relapsed acute lymphoblastic leukemia. Furthermore, goal is to set up a large international study group platform allowing for optimization of standard treatment strategies and integration of new agents.
Timeline
- Start
- 2014-05
- Primary completion
- 2023-07-31
- Completion
- 2023-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Epratuzumab | Monoclonal antibody | — | — |